FTO rs62033406 A>G associated with the risk of osteonecrosis of the femoral head among the Chinese Han population

Yuan Wang, Wei Zhong, Shaofeng Wang, Yang Yang and Bing Zhu*

Abstract

**Background:** Fat mass and obesity-related (FTO) mRNA was downregulated in osteonecrosis patients. The study aimed to evaluate the correlation between FTO polymorphisms and the susceptibility of osteonecrosis of the femoral head (ONFH).

**Methods:** Six polymorphisms in FTO were genotyped via the Agena MassARRAY in 498 ONFH patients and 498 healthy controls. Multiple genetic models were used to assess the correlation between FTO polymorphisms and ONFH risk by SNPStats. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a logistic regression model adjusted by age, gender, smoking and drinking.

**Results:** The risk-increasing association of rs62033406 A>G with ONFH was found (OR = 1.25, 95% CI 1.05–1.50, \(p = 0.014\)). Specially, FTO rs62033406 A>G was related to the risk of ONFH in the subgroup at age > 51 years (OR = 1.25, \(p = 4.00 \times 10^{-4}\)), females (OR = 1.74, \(p = 1.00 \times 10^{-4}\)), smokers (OR = 1.82, \(p = 0.005\)) and drinkers (OR = 1.89, \(p = 0.002\)), respectively. The best multi–loci model was the five–loci model, a combination of rs9930333 T>G, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G (testing accuracy, 0.5351; \(p = 0.0004\); cross–validation consistency, 10/10).

**Conclusion:** Our study first revealed that FTO rs62033406 A>G was a risk factor for ONFH among the Chinese Han population, which might provide the new candidate gene for elucidating the pathogenesis of ONFH.

**Keywords:** Osteonecrosis of the femoral head, FTO polymorphisms, Risk factor, MDR analysis

Introduction

Osteonecrosis of the femoral head (ONFH), also defined as avascular necrosis of the femoral head, is characterized by bone cell death caused by venous stasis of the femoral head or impaired or interrupted arterial blood supply [1]. The onset of ONFH remains increasing every year around the world. It is estimated that there are 8.12 million adults with ONFH in China alone [2]. The average age of the affected patients is 50.4 years and there is a male to female ratio of 2.1:1 [3]. ONFH is a multifactorial disease caused by a complex interplay of genetic and environmental factors. The use of corticosteroids, alcohol overconsumption, smoking, high blood lipid level, and obesity are all high-risk factors for ONFH [4]. In recent studies, emerging lines of evidence have suggested genetic factors and hereditary forms play a pivotal role in ONFH development [5]. For example, NOS3, IL-1B, ABCB1 and CYP450 single nucleotide polymorphisms (SNPs) were closely related to the susceptibility of ONFH [6–8]. However, many variants contributed to ONFH remain to be identified.
The fat mass and obesity-related (FTO) gene has been reported to be involved in common obesity and body mass index [9]. Deletion of FTO in mice might lead to increased death of osteoblasts and bone loss, suggesting that the function of FTO was to maintain bone mass and to protect osteoblasts from genotoxic damage [10]. Recent study indicated that overexpression of FTO induces osteogenic differentiation of C3H10T1/2 cells [11]. Pervious findings demonstrated that GDF11-FTO-PPARγ axis inhibited bone formation and promoted the transformation of osteoporotic bone marrow mesenchymal stem cells (BMSCs) to adipocytes during osteoporosis [12]. These studies indicated that FTO played an important role in the death and differentiation of osteoblasts. FTO mRNA was downregulated in osteoporosis patients and osteonecrosis patients [13]. FTO polymorphisms have been investigated in many bone-related diseases, such as hip fracture, osteoporosis and osteoarthritis [14–16], but not in ONFH. Therefore, research on the possible association between FTO gene and ONFH may be particularly interesting due to its potential biological significance.

Here, six SNPs (rs9930333 T>G, rs11642015 C>T, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G) in FTO were randomly selected for genotyping to assess the contribution of these SNPs to ONFH risk in the Chinese Han population, which might contribute to knowing about the role of FTO in the development of ONFH. Stratified analysis by age, sex, smoking, and drinking were used to explore the different association graph patterns in each subgroup, which might reflect the potential differences in their pathophysiology and ONFH risk factors.

### Materials and methods

#### Study participants

In this study, we recruited 498 patients with ONFH and 498 healthy controls from the Affiliated Hospital of Weifang Medical University and Second Affiliated Hospital of Inner Mongolia Medical University from April 2015 to June 2021. All subjects were genetically unrelated Chinese Han population. Patients with ONFH had common clinical manifestations of hip pain, joint dysfunction, and lower limb muscular atrophy. ONFH was diagnosed by an X-ray examination, bone scan analyses and additional magnetic resonance imaging. Diagnostic criteria for imaging include the collapse of the femoral head, increased subchondral bone density, hip joint narrowness, and trabecular and marrow necrosis on histology. The inclusion criteria for health controls were defined as following criteria: no symptoms of hip disease, no tumor, no any lesions of anteroposterior and frog-leg lateral pelvic radiographs, no severe chronic diseases, and no history of thromboembolic disease. Demographic characteristics (age, gender, smoking, and drinking) and clinical data were obtained via a structured questionnaire and medical records, respectively. The identification of smokers and drinkers was based on the subjects’ self-report of whether they smoked or drank alcohol. For smoking, participants were classified as non-smokers (never) or smokers (including former or current smokers). Subjects who smoked one cigarette per day were classified as current smokers. For alcohol consumption, participants were classified as non-drinkers (never) or drinkers (including former or current alcohol drinkers). Subjects who drank at least 100 g of alcohol a week were considered drinkers.

The study protocol was approved by the institutional review boards of Affiliated Hospital of Weifang Medical University, and was conducted in accordance with the ethical standards of the Declaration of Helsinki. Written informed consents were obtained from all participants.

#### SNP selection and genotyping

Subsequently, 5 mL of peripheral blood from participants were collected into ethylene diamine tetraacetic acid (EDTA) tubes. Genomic DNA was isolated using genomic DNA purification Kit (GoldMag Co. Ltd. Xi’an City, China) and stored at −80 °C until further analysis. The concentration and purity of DNA was measured by a Nanodrop 2000 (Thermo Scientific, Waltham, MA, USA).

We obtained the physical position of the FTO gene on the chromosome 16:53,701,692–54,158,512 and downloaded the ped file and info file for FTO variations in the CHB and CHS population through the eGRCh37 (http://asia.ensembl.org/Homo_sapiens/Info/Index) database. Using Haploview software, we selected SNPs based on HWE > 0.01, MAF > 0.05, and Min Genotype > 75%. We further combined MassARRAY primer design software, HWE > 0.05, MAF > 0.05 and the call rate > 95% in our study population. Among the remaining SNPs, six candidate SNPs (rs9930333 T>G, rs11642015 C>T, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G) in FTO were randomly selected in order to study their potential role in ONFH risk. The potential functions of these polymorphisms were evaluated through the HaploReg v4.1 database (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php) and RegulomeDB database (https://regulome.stanford.edu/ regulome-search/).

Agena MassARRAY system (Agena, San Diego, CA, USA) was used for SNPs genotyping according to the manufacturer instructions. The design of genotyping primers (Additional file 1: Table S1) and data management was carried out with incorporated software. The randomly selected samples (about 10%) were
re-genotyped to control quality, and the reproducibility was 100%.

Statistical analysis
The student t test for continuous variables and chi-square test for categorical variables were used to compare the differences between cases and controls, respectively. The genotype frequency of each SNP in the control and the case subjects were conformed to HWE by the χ² test. Multiple genetic models were used to assess the contribution of FTO polymorphisms to the risk of ONFH by SNPSstats (https://www.snpstats.net/start.htm). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a logistic regression model adjusted by age, gender, smoking and drinking. Further stratification analysis was performed to explore the impact of FTO SNPs on ONFH based on age, gender, smoking, drinking, and clinical stages. The noteworthy of the significant associations were assessed by false-positive report probability (FPRP) analysis, with 0.2 as a FPRP threshold and p<0.05 was the threshold for statistical significance, whereas a value of corrected p<0.05/6 was considered significant after Bonferroni correction.

Results
Characteristics of the participants
A total of 996 subjects (498 ONFH patients and 498 healthy controls) were included. The demographic and clinical information of subjects were shown in Table 1. The mean age of cases and controls were 51.77±14.55 years and 50.38±14.52 years, respectively. ONFH cases and controls were matched in age (p=0.132), but there was a difference in sex (p=0.046). The distribution of smoking, red blood cell (RBC), white blood cell (WBC), hemoglobin, platelet, leukocyte, monocytes, urea, and creatinine between the two groups were different (p<0.05).

Association between FTO SNPs and the risk of ONFH
Six SNPs (rs9930333 T > G, rs11642015 C > T, rs1558902 T > A, rs56094641 A > G, rs3751812 G > T, and rs62033406 A > G) in FTO were genotyped, and the basic information of all SNPs were listed in Table 2. All selected polymorphisms were in HWE (p>0.05), and the call rate was >99.5%. The potential function of these polymorphisms by HaploReg v4.1 and RegulomeDB databases was displayed in Table 2.

In the allelic model, rs62033406-G was related to an increased risk of ONFH (OR=1.22, 95% CI 1.02–1.46, p=0.028). The other SNPs did not appear to be related to the susceptibility to ONFH. Genotypic model analysis was used to assess the associations of FTO SNPs with ONFH risk (Table 3). The risk-increasing association of rs62033406-G was related to an increase in risk (OR=1.54, 95% CI 1.14–2.07; OR=1.52, 95% CI 1.06–2.18; p=0.011), dominant (OR=1.53, 95% CI 1.16–2.03, p=0.003), and log-additive (OR=1.25, 95% CI 1.05–1.50, p=0.014) models. The significance of the dominant model still existed after Bonferroni correction.

Stratification analysis for the contribution of FTO SNPs to ONFH risk
To identify subgroup specific associations, we performed stratification analysis based on the major risk factors, such as age, sex, smoking, alcohol drinking and clinical stages (Table 4; Additional file 1: Tables S2, and S3). The results displayed that FTO rs62033406-G was related to the risk of ONFH in the subgroup at age >51 years.

Table 1 Characteristics of patients with ONFH and controls

|Variable| Cases | Control | p       |
|---|---|---|---|
|N| 498 | 498 | |
|Age (year, mean±SD)| 51.77±14.55 | 50.38±14.52 | 0.132 |
|>51| 273 (54.8%) | 236 (47.4%) | |
|≤51| 225 (45.2%) | 262 (52.6%) | |
|Gender| | | |
|Males| 280 (56.2%) | 311 (62.4%) | 0.046 |
|Females| 218 (43.8%) | 187 (37.6%) | |
|Smoking| | | |
|Yes| 219 (44.0%) | 269 (54.0%) | 0.002 |
|No| 279 (56.0%) | 229 (46.0%) | |
|Alcohol consumption| | | |
|Yes| 265 (53.2%) | 256 (51.4%) | 0.568 |
|No| 233 (46.8%) | 242 (48.6%) | |
|Stage| | | |
|III/IV| 192 (38.6%) | | |
|I/II| 67 (13.5%) | | |
|Missing| 235 (47.2%) | | |
|RBC (10⁹/L)| 3.91±0.83 | 4.90±0.48 | <0.001 |
|WBC (10⁹/L)| 7.67±2.53 | 5.94±1.59 | <0.001 |
|Hemoglobin (g/L)| 118.35±20.11 | 149.76±17.03 | <0.001 |
|Platelet (10⁹/L)| 197.74±72.79 | 222.23±58.94 | <0.001 |
|Leukocyte (10⁹/L)| 1.60±0.65 | 1.87±0.59 | <0.001 |
|Monocytes (10⁹/L)| 0.55±0.26 | 0.42±0.16 | <0.001 |
|Serum uric acid (μmol/L)| 266.67±88.17 | 322.64±80.7 | 0.337 |
|Urea (μmol/L)| 5.29±5.35 | 5.06±1.27 | <0.001 |
|Creatinine (μmol/L)| 57.32±16.53 | 67.65±12.57 | <0.001 |

ONFH, osteonecrosis of the femoral head; RBC, red blood cell; WBC, white blood cell
p values were calculated by χ² test or Student’s t test
Bold indicate that p<0.05 indicates statistical significance
| SNPs ID   | Chr: position (minor/major) | Alleles (minor/major) | Frequency (MAF) | Function | P value for HWE | Call rate | OR (95% CI) | P   | Haploreg                                                                 | Regulome DB                  |
|-----------|-----------------------------|-----------------------|-----------------|----------|-----------------|-----------|-------------|-----|--------------------------------------------------------------------------|-------------------------------|
| rs9930333 | 16:53,766,065 G/T           |          0.154         | 0.157           | Intrinsic | 0.610           | 0.105     | 0.98 (0.77–1.25) | 0.853 | Enhancer histone marks, Motifs changed                                    | TF binding or DNase peak         |
| rs11642015| 16:53,768,582 T/C           |          0.109         | 0.107           | Intrinsic | 0.817           | 0.401     | 1.02 (0.77–1.35) | 0.885 | Promoter histone marks, Enhancer histone marks, DNase, Proteins bound, Motifs changed | TF binding + DNase peak         |
| rs1558902 | 16:53,769,662 A/T           |          0.105         | 0.106           | Intrinsic | 0.814           | 0.524     | 0.99 (0.74–1.32) | 0.942 | Promoter histone marks, Enhancer histone marks, DNase, Motifs changed   | TF binding or DNase peak         |
| rs56094641| 16:53,772,541 G/A           |          0.110         | 0.108           | Intrinsic | 0.999           | 0.427     | 1.02 (0.77–1.35) | 0.886 | Promoter histone marks, Enhancer histone marks, DNase, Motifs changed   | Motif hit                      |
| rs3751812 | 16:53,784,548 T/G           |          0.107         | 0.108           | Intrinsic | 0.999           | 0.561     | 0.98 (0.74–1.31) | 0.910 | Enhancer histone marks, DNase, Motifs changed                            | TF binding + any motif + DNase peak |
| rs62033406| 16:53,790,314 G/A           |          0.483         | 0.434           | Intrinsic | 0.465           | 0.215     | 0.99 (1.02–1.46) | 0.028 | Enhancer histone marks, Motifs changed                                   | Motif hit                      |

Data from Haploreg (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php), and Regulome DB (https://regulome.stanford.edu/regulome-search/)

ONFH, osteonecrosis of the femoral head; SNP, single nucleotide polymorphism; IS, ischemic stroke; MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium

Bold indicate that $p < 0.05$ indicates statistical significance
Table 3  Association between FTO polymorphisms and ONFH risk

| SNP ID    | Model     | Genotype | Case     | Control  | OR (95% CI)  | P value | AIC   | BIC   |
|-----------|-----------|----------|----------|----------|--------------|---------|-------|-------|
| rs930333  | Codominant| T/T      | 362 (72.7%) | 352 (70.7%) | 1             | 0.210   | 1371.9 | 1406.2 |
|           |           | G/T      | 119 (23.9%) | 136 (27.3%) | 0.85 (0.64–1.14) |         |       |       |
|           |           | G/G      | 17 (3.4%)  | 10 (2%)   | 1.66 (0.75–3.70) |         |       |       |
|           | Dominant  | T/T      | 362 (72.7%) | 352 (70.7%) | 1             | 0.490   | 1372.5 | 1401.9 |
|           |           | G/T-G/G  | 136 (27.3%) | 146 (29.3%) | 0.91 (0.68–1.20) |         |       |       |
|           | Recessive | T/T-G/T  | 481 (96.6%) | 488 (98%) | 1             | 0.170   | 1371.1 | 1400.5 |
|           |           | G/G      | 17 (3.4%)  | 10 (2%)   | 1.74 (0.78–3.85) |         |       |       |
|           | Log-additive | – | – | – | 0.98 (0.77–1.25) | 0.860 | 1373 | 1402.4 |
| rs11642015 | Codominant | C/C      | 397 (79.7%) | 397 (79.7%) | 1 | 0.890 | 1374.8 | 1409.1 |
|           |           | T/T      | 93 (18.7%)  | 95 (19.1%) | 0.99 (0.72–1.37) |         |       |       |
|           |           | T/T      | 8 (1.6%)   | 6 (1.2%)  | 1.30 (0.44–3.83) |         |       |       |
|           | Dominant  | C/C      | 397 (79.7%) | 397 (79.7%) | 1 | 0.940 | 1373 | 1402.4 |
|           |           | T/C-T/T  | 101 (20.3%) | 101 (20.3%) | 1.01 (0.74–1.38) |         |       |       |
|           | Recessive | C/C-C/T  | 490 (98.4%) | 492 (98.8%) | 1 | 0.620 | 1372.8 | 1402.2 |
|           |           | T/T      | 8 (1.6%)   | 6 (1.2%)  | 1.31 (0.45–3.83) |         |       |       |
|           | Log-additive | – | – | – | 1.03 (0.78–1.36) | 0.840 | 1373 | 1402.4 |
| rs1558902  | Codominant | T/T      | 400 (80.3%) | 398 (79.9%) | 1 | 0.970 | 1374.9 | 1409.3 |
|           |           | A/T      | 91 (18.3%)  | 94 (18.9%) | 0.98 (0.71–1.35) |         |       |       |
|           |           | A/A      | 7 (1.4%)   | 6 (1.2%)  | 1.33 (0.37–4.33) |         |       |       |
|           | Dominant  | T/T      | 400 (80.3%) | 398 (79.9%) | 1 | 0.940 | 1373 | 1402.4 |
|           |           | A/T-A/A  | 98 (19.7%)  | 100 (20.1%) | 0.99 (0.72–1.35) |         |       |       |
|           | Recessive | T/T-A/T  | 491 (98.6%) | 492 (98.8%) | 1 | 0.820 | 1373 | 1402.4 |
|           |           | A/A      | 7 (1.4%)   | 6 (1.2%)  | 1.31 (0.38–3.44) |         |       |       |
|           | Log-additive | – | – | – | 1.00 (0.75–1.33) | 0.990 | 1373 | 1402.4 |
| rs56094641 | Codominant | A/A      | 396 (79.5%) | 396 (79.5%) | 1 | 0.890 | 1374.8 | 1409.1 |
|           |           | G/A      | 94 (18.9%)  | 96 (19.3%) | 0.99 (0.72–1.37) |         |       |       |
|           |           | G/G      | 8 (1.6%)   | 6 (1.2%)  | 1.31 (0.44–3.83) |         |       |       |
|           | Dominant  | A/A      | 396 (79.5%) | 396 (79.5%) | 1 | 0.950 | 1373 | 1402.4 |
|           |           | G/A-G/G  | 102 (20.5%) | 102 (20.5%) | 1.01 (0.74–1.38) |         |       |       |
|           | Recessive | A/A-G/A  | 490 (98.4%) | 492 (98.8%) | 1 | 0.620 | 1372.8 | 1402.2 |
|           |           | G/G      | 8 (1.6%)   | 6 (1.2%)  | 1.31 (0.45–3.83) |         |       |       |
|           | Log-additive | – | – | – | 1.03 (0.77–1.36) | 0.850 | 1373 | 1402.4 |
| rs3751812  | Codominant | G/G      | 397 (80%)  | 396 (79.5%) | 1 | 0.960 | 1372.7 | 1407 |
|           |           | G/T      | 92 (18.6%)  | 96 (19.3%) | 0.98 (0.71–1.35) |         |       |       |
|           |           | T/T      | 7 (1.4%)   | 6 (1.2%)  | 1.34 (0.38–3.44) |         |       |       |
|           | Dominant  | G/G      | 397 (80%)  | 396 (79.5%) | 1 | 0.920 | 1370.7 | 1400.1 |
|           |           | G/T-G/T  | 99 (20%)   | 102 (20.5%) | 0.98 (0.72–1.35) |         |       |       |
|           | Recessive | G/G-G/T  | 489 (98.6%) | 492 (98.8%) | 1 | 0.810 | 1370.7 | 1400.1 |
|           |           | T/T      | 7 (1.4%)   | 6 (1.2%)  | 1.34 (0.38–4.35) |         |       |       |
|           | Log-additive | – | – | – | 1.00 (0.75–1.32) | 0.980 | 1370.7 | 1400.2 |
| rs62033406 | Codominant | A/A      | 126 (25.4%) | 164 (32.9%) | 1 | 0.011 | 1364.7 | 1399 |
|           |           | G/A      | 262 (52.7%) | 236 (47.4%) | 1.54 (1.14–2.07) |         |       |       |
|           |           | G/G      | 109 (21.9%) | 98 (19.7%) | 1.52 (1.06–2.18) |         |       |       |
|           | Dominant  | A/A      | 126 (25.4%) | 164 (32.9%) | 1 | 0.003* | 1362.7 | 1392.1 |
|           |           | G/A-G/G  | 371 (74.7%) | 334 (67.1%) | 1.53 (1.16–2.03) |         |       |       |
|           | Recessive | A/A-G/A  | 388 (78.1%) | 400 (80.3%) | 1 | 0.350 | 1370.8 | 1400.2 |
|           |           | G/G      | 109 (21.9%) | 98 (19.7%) | 1.16 (0.85–1.58) |         |       |       |
|           | Log-additive | – | – | – | 1.25 (1.05–1.50) | 0.014 | 1365.5 | 1394.9 |

ONFH, osteonecrosis of the femoral head; SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval; AIC, akaike information criterion; BIC, Bayesian information criterion

*p values were calculated using logistic regression analysis adjusted by gender, age, smoking and drinking

Bold indicate that p < 0.05 means the data is statistically significant

* p indicate that after Bonferroni correction (p < 0.05/6) means the data is statistically significant
(codominant: OR = 2.00, OR = 2.39, \( p = 7.00 \times 10^{-4} \); dominant: OR = 2.11, \( p = 2.00 \times 10^{-4} \); and log-additive: OR = 1.25, \( p = 4.00 \times 10^{-4} \)), females (codominant: OR = 2.42, OR = 2.75, \( p = 1.00 \times 10^{-4} \); dominant: OR = 2.51, \( p < 0.0001 \); and log-additive: OR = 1.74, \( p = 1.00 \times 10^{-4} \)), smokers (codominant: OR = 1.82, OR = 1.81, \( p = 0.020 \); dominant: OR = 1.82, \( p = 0.005 \); and log-additive: OR = 1.36, \( p = 0.023 \)) and drinkers (codominant: OR = 1.91, OR = 1.84, \( p = 0.009 \); dominant: OR = 1.89, \( p = 0.002 \); and log-additive: OR = 1.39, \( p = 0.014 \)), respectively. After Bonferroni correction, rs62033406-G was associated with an increased incidence in the subgroup at age > 51 years (codominant, dominant, and log-additive), females (codominant, dominant, and log-additive), smokers (dominant), and drinkers (dominant), respectively. Besides, rs9930333 GT genotype was related to a reduced risk of ONFH compared to the TT genotype (OR = 0.66, \( p = 0.030 \)). However, no significant relationship of selected polymorphisms to ONFH in the stratified analysis by clinical stages was found (Additional file 1: Table S3). These results of overall analysis and stratification analysis was shown in Fig. 1.

**FPRP analysis for the positive findings**

FPRP analysis was performed to interrogate whether the significant findings were deserving attention (Table 5). At the prior probability level of 0.1, the significant association for rs62033406-G (FPRP = 0.081, 0.061, and 0.132) remained noteworthy in the overall analysis. Moreover, the associations of rs62033406-G with ONFH susceptibility were also positive in the subgroup at age > 51 years at the prior probability level of 0.01, females at the prior probability level of 0.001, and smokers and drinkers at the prior probability level of 0.1, respectively.

**MDR analysis for the contribution of FTO SNPs to ONFH risk**

MDR analysis was applied to evaluate the effect of SNP-SNP interaction on ONFH risk (Figs. 2, 3; Table 6). Table 6 displayed the results for one- to six-locus models. Rs62033406 A>G was the best single-locus model for ONFH risk, with the highest testing accuracy (0.5382, \( p = 0.008 \)) and perfect cross-validation consistency (10/10). The best multi-loci model was the five-loci model, a combination of rs9930333 T>G, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G (testing accuracy, 0.5351; \( p = 0.0004 \); cross-validation consistency, 10/10). The dendrogram plot (Fig. 2) described the SNP-SNP interactions and recapitulated the main and/or interaction effect for each pairwise combination of attributes. The fruchterman-Reingold plot (Fig. 3) revealed that rs62033406 had the information gain (0.60%) of individual attribute regarding ONFH.

**Discussion**

Here, six SNPs in *FTO* were examined in 996 participants to investigate the susceptibility to ONFH risk in the Chinese Han population. This study was the first to demonstrate that rs62033406 A>G contributed to an increased risk of ONFH under the allele, genotype, dominant and log-additive models. Specially, *FTO* rs62033406 A>G was related to ONFH susceptibility in the subgroup at age > 51 years, females, smokers, and drinkers, respectively. MDR analysis displayed that rs62033406 A>G was the best single-locus model for ONFH risk, and the best multi-loci model was the five-locus model, a combination of rs9930333 T>G, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G. These results indicate that *FTO* SNPs may have an important role in ONFH risk among the Han Chinese population, which have provided insights into ONFH occurrence.

*FTO* mRNA was downregulated in osteonecrosis patients. During osteogenic differentiation, *FTO* induced the expression of osteoblast biomarkers ALPL and OPN [13]. Some recent studies suggested that genetic polymorphisms of *FTO* might affect the expression of the adjacent genes and were associated with disease [19]. However, no studies have evaluated the impact of *FTO* polymorphisms on ONFH risk. Here, six SNPs (rs9930333 T>G, rs11642015 C>T, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G) in the *FTO* gene were genotyped to assess the risk-association with ONFH occurrence. HaploReg v4.1 database displayed that these SNPs might be associated with promoter/Enhancer histone marks, DNase, proteins bound, and motifs changed [20]. This study was the first to demonstrate that rs62033406 A>G contributed to an increased risk of ONFH in the Chinese Han population after Bonferroni correction. Several studies provided increasing evidence to support that intronic SNPs confer susceptibilities by affecting gene expression [21, 22]. SNPs within intron of the *FTO* gene are related to *FTO* transcript levels [23]. In *silico*, rs62033406 A>G located in the intronic regions of the *FTO* gene could be as a possible enhancer activity or motifs change, which may affect the activity or expression of *FTO* and may change the motif of functional DNA binding sites and thus impact the regulation of transcription and alternative splicing in ONFH occurrence. However, the hypothesis required further experimental confirmation. In future, we would design detailed experiments to further explore the association between rs62033406 A>G and *FTO* expression and the biological functions of rs62033406 in ONFH occurrence.

ONFH primarily affects young to middle-aged adults, the mean age at diagnosis is 48 years in China, with majority of their patients were between 30 and 65 years...
Table 4  Association between FTO polymorphisms and ONFH risk according to the stratification analysis

| SNP ID      | Genotype | Case (Age, years > 51) | Control (Age, years ≤ 51) | OR (95% CI)       | P value | Case (Gender Males) | Control (Gender Females) | OR (95% CI)       | P value |
|-------------|----------|------------------------|---------------------------|--------------------|---------|---------------------|--------------------------|--------------------|---------|
| rs62033406  | Codominant A/A | 64 (23.4%) | 88 (37.3%) | 1 | 7.00 × 10^-4 | 62 (27.7%) | 76 (29%) | 1 | 0.650 |
| rs62033406  | Codominant G/A | 143 (52.4%) | 108 (45.8%) | 2.00 (1.32–3.04) | 119 (53.1%) | 128 (48.9%) | 1.15 (0.76–1.76) | 0.510 |
| rs62033406  | Codominant G/G | 66 (24.2%) | 40 (16.9%) | 2.39 (1.42–4.00) | 43 (19.2%) | 58 (22.1%) | 0.95 (0.56–1.59) | 0.910 |
| rs62033406  | Dominant A/A | 64 (23.4%) | 88 (37.3%) | 1 | 7.00 × 10^-4 | 62 (27.7%) | 76 (29%) | 1 | 0.650 |
| rs62033406  | Dominant G/A | 143 (52.4%) | 108 (45.8%) | 2.00 (1.32–3.04) | 119 (53.1%) | 128 (48.9%) | 1.15 (0.76–1.76) | 0.510 |
| rs62033406  | Dominant G/G | 66 (24.2%) | 40 (16.9%) | 2.39 (1.42–4.00) | 43 (19.2%) | 58 (22.1%) | 0.95 (0.56–1.59) | 0.910 |
| rs62033406  | Log-additive – | – | – | 1.59 (1.22–2.05) | 4.00 × 10^-4 | – | – | 0.99 (0.76–1.28) | 0.910 |
| rs9930333   | Codominant T/T | 206 (73.6%) | 209 (67.2%) | 1 | 0.030 | 156 (71.6%) | 143 (76.5%) | 1 | 0.650 |
| rs9930333   | G/T | 63 (22.5%) | 96 (30.9%) | 0.66 (0.45–0.96) | 56 (25.7%) | 40 (21.4%) | 1.24 (0.77–1.99) | 0.350 |
| rs9930333   | G/G | 11 (3.9%) | 6 (1.9%) | 1.86 (0.67–5.16) | 6 (2.8%) | 4 (2.1%) | 1.24 (0.77–1.99) | 0.350 |
| rs9930333   | Dominant T/T | 206 (73.6%) | 209 (67.2%) | 1 | 0.030 | 156 (71.6%) | 143 (76.5%) | 1 | 0.650 |
| rs9930333   | G/T-G/G | 74 (26.4%) | 122 (32.8%) | 0.73 (0.51–1.04) | 62 (28.4%) | 44 (23.5%) | 1.24 (0.79–1.96) | 0.350 |
| rs9930333   | Recessive T/T-G/T | 269 (96.1%) | 305 (98.1%) | 1 | 0.150 | 212 (97.2%) | 183 (97.9%) | 1 | 0.810 |
| rs9930333   | G/G | 11 (3.9%) | 6 (1.9%) | 2.08 (0.62–5.76) | 6 (2.8%) | 4 (2.1%) | 1.24 (0.79–1.96) | 0.350 |
| rs62033406  | Codominant A/A | 74 (26.5%) | 82 (26.4%) | 1 | 0.290 | 52 (23.9%) | 82 (43.9%) | 1 | 0.650 |
| rs62033406  | G/A | 150 (53.8%) | 162 (52.1%) | 1.09 (0.73–1.60) | 112 (51.4%) | 74 (39.6%) | 2.42 (1.52–3.83) | 0.370 |
| rs62033406  | G/G | 55 (19.7%) | 67 (21.5%) | 0.96 (0.59–1.55) | 54 (24.8%) | 31 (16.6%) | 2.75 (1.55–4.86) | 0.370 |
| rs62033406  | Dominant A/A | 74 (26.5%) | 82 (26.4%) | 1 | 0.810 | 52 (23.9%) | 82 (43.9%) | 1 | 0.650 |
| rs62033406  | G/A-G/G | 205 (73.5%) | 229 (73.6%) | 1 | 0.630 | 166 (76.2%) | 105 (56.1%) | 2.51 (1.63–3.87) | 0.370 |
| rs62033406  | Recessive A/A-G/A | 224 (80.3%) | 244 (78.5%) | 1 | 0.98 (0.60–1.56) | 54 (24.8%) | 31 (16.6%) | 1.65 (1.00–2.72) | 0.370 |
| rs62033406  | G/G | 55 (19.7%) | 67 (21.5%) | 0.90 (0.60–1.56) | 54 (24.8%) | 31 (16.6%) | 1.65 (1.00–2.72) | 0.370 |
| Smoking     | Codominant A/A | 44 (20.1%) | 82 (30.5%) | 1 | 0.020 | 82 (29.5%) | 82 (35.8%) | 1 | 0.290 |
| Smoking     | G/A | 125 (57.1%) | 134 (49.8%) | 1.82 (1.16–2.84) | 137 (49.3%) | 102 (44.5%) | 1.36 (0.91–2.03) | 0.370 |
| Smoking     | G/G | 50 (22.8%) | 53 (19.7%) | 1.81 (1.06–3.09) | 59 (21.2%) | 45 (19.6%) | 1.34 (0.81–2.22) | 0.370 |
| Smoking     | Dominant A/A | 44 (20.1%) | 82 (30.5%) | 1 | 0.020 | 82 (29.5%) | 82 (35.8%) | 1 | 0.290 |
| Smoking     | G/A-G/G | 175 (79.9%) | 187 (69.5%) | 1.82 (1.19–2.78) | 196 (70.5%) | 147 (64.2%) | 1.35 (0.93–1.98) | 0.370 |
| Smoking     | Recessive A/A-G/A | 169 (77.2%) | 216 (80.3%) | 1 | 0.410 | 219 (78.8%) | 184 (80.3%) | 1 | 0.610 |
| Smoking     | G/G | 50 (22.8%) | 53 (19.7%) | 1.82 (1.19–2.78) | 196 (70.5%) | 147 (64.2%) | 1.35 (0.93–1.98) | 0.370 |
| Smoking     | Log-additive – | – | – | 1.36 (1.04–1.77) | 0.023 | – | – | 1.18 (0.92–1.51) | 0.190 |
Given that age is the risk factor for ONFH, we further explored the effect of FTO variant on susceptibility to ONFH in the stratification analysis by age. A study reported that the median of ONFH patients was 50 years [25]. Besides, the mean ages of ONFH patients and the controls in the study were 51.77 ± 14.55 years and 50.38 ± 14.52 years, respectively. To explore the contribution of age, we divided the cases and controls into two groups as ≤ 51 years and > 51 years, respectively. The results displayed that rs62033406 A>G was related to the risk of ONFH in the subgroup at age > 51 years but not in the subjects with age ≤ 51 years, which indicated that the influence of rs62033406 A>G on ONFH susceptibility presented age difference. Moreover, the prevalence rate was higher in men than in women in China [2]. We noticed that rs62033406 A>G affected ONFH risk in females but not in males, suggesting that genetic susceptibility to ONFH might differ by sex. Specially, rs62033406 A>G was associated with the higher ONFH risk after Bonferroni correction in the subgroup at age > 51 years and in females. The differential genetic association pattern in subjects aged > 51 years and in females might be influenced by their hormonal, genetic, and behavioral factors.

Table 4 (continued)

| SNP ID      | Model | Genotype | Case | Control | OR (95% CI) | P value |
|-------------|-------|----------|------|---------|-------------|---------|
| rs62033406  | Codominant | A/A     | 58 (21.9%) | 81 (31.6%) | 1          | 0.002*     |
|             |       | G/A     | 150 (59.6%) | 137 (54%) | 1.91 (1.24–2.93) | 0.021     |
|             |       | G/G     | 57 (21.5%) | 48 (18.9%) | 1.84 (1.08–3.12) | 0.030     |
| Dominant    |       | A/A     | 58 (21.9%) | 81 (31.6%) | 1          | 0.002*     |
|             |       | G/A-G/G | 207 (78.1%) | 175 (68.4%) | 1.89 (1.25–2.84) | 0.014     |
|             |       | G/G     | 57 (21.5%) | 48 (18.9%) | 1.19 (0.77–1.86) | 0.500     |
| Recessive   |       | A/A-G/A | 208 (78.5%) | 208 (81.2%) | 0.430 | 0.014     |
|             |       | G/G     | 57 (21.5%) | 48 (18.9%) | 1.12 (0.72–1.74) | 0.500     |

ONFH, osteonecrosis of the femoral head; SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval

*p values were calculated using logistic regression analysis adjusted by gender, age, smoking and/or drinking
Bold indicate that p<0.05 means the data is statistically significant
*p indicate that after Bonferroni correction (p<0.05/6) means the data is statistically significant

Fig. 1 Forest plot of FTO polymorphisms and ONFH susceptibility. The horizontal lines represent the study-specific ORs and 95% CIs.
Smoking and alcohol intake are modifiable lifestyle-related risk factors for ONFH [26]. A meta-analysis showed that smokers were at a higher risk of ONFH [27]. Alcohol intake is positively related to an increased risk of ONFH in a non-linear pattern [28]. Specifically, FTO rs62033406 A>G was related to the risk of ONFH in smokers and drinkers, but not in non-smokers and non-drinkers respectively. After Bonferroni correction, rs62033406 A>G was associated with an increased incidence in smokers and drinkers under the dominant model. These findings emphasize the importance of considering gene-behavioral habit in association studies between genetic and ONFH risk. These results might emphasize the importance of considering heterogeneity in genetic and ONFH association studies.

Given that ONFH is a complex polygenic disease, SNP-SNP interaction studies may help to discover the risk factors of ONFH. Of note, MDR is a powerful method to detect SNP-SNP interactions without main gene effects for complex diseases in case–control studies [29]. Further, the MDR was used to analyse the interactions of these six SNPs, the result suggested that rs62033406 A>G was the best single–locus model for ONFH risk, which was consistent with the results of logistic regression analysis. The Fruchterman-Reingold revealed that rs62033406 had the information gain (0.60%) of individual attribute regarding ONFH. The best multi–loci model was the five-locus model, a combination of rs9930333 T>G, rs1558902 T>A, rs56094641 A>G, rs3751812 G>T, and rs62033406 A>G, which might further support the multi-factor model contributing to ONFH occurrence. Furthermore, rs62033406 was found to have a significant combinatorial effect with four other SNPs. This hints that the combination of high-risk genotypes carrying these

### Table 5 False-positive report probability for the associations of FTO polymorphisms with ONFH risk

| Group/ SNPs ID | Model         | OR (95% CI) | Prior probability |
|---------------|---------------|-------------|-------------------|
|               |               |             | 0.25  | 0.1    | 0.01 | 0.001 | 0.0001 |
| Overall       | Codominant    | 1.54 (1.14–2.07) | 0.029 | 0.081 | 0.492 | 0.907 | 0.990 |
|               | Dominant      | 1.52 (1.06–2.18) | 0.127 | 0.304 | 0.828 | 0.980 | 0.998 |
|               | Log-additive  | 1.53 (1.16–2.03) | 0.021 | 0.061 | 0.416 | 0.878 | 0.986 |
|               |               | 1.25 (1.05–1.50) | 0.048 | 0.132 | 0.625 | 0.944 | 0.994 |
| Age > 51 years| Codominant    | 2.00 (1.32–3.04) | 0.007 | 0.021 | 0.189 | 0.701 | 0.959 |
|               | Dominant      | 2.39 (1.42–4.00) | 0.011 | 0.032 | 0.266 | 0.786 | 0.973 |
|               | Log-additive  | 2.11 (1.42–3.13) | 0.002 | 0.005 | 0.049 | 0.343 | 0.839 |
|               |               | 1.59 (1.22–2.05) | 0.003 | 0.009 | 0.095 | 0.515 | 0.914 |
| Males         | Codominant    | 0.66 (0.45–0.96) | 0.157 | 0.358 | 0.860 | 0.984 | 0.998 |
| Females       | Codominant    | 2.42 (1.52–3.83) | 0.002 | 0.007 | 0.071 | 0.437 | 0.886 |
|               | Dominant      | 2.75 (1.54–4.86) | 0.011 | 0.032 | 0.265 | 0.785 | 0.973 |
|               | Log-additive  | 2.51 (1.63–3.87) | 0.001 | 0.002 | 0.020 | 0.169 | 0.671 |
|               |               | 1.74 (1.31–2.31) | 0.003 | 0.007 | 0.077 | 0.455 | 0.893 |
| Smokers       | Codominant    | 0.036 | 0.102 | 0.556 | 0.927 | 0.992 |
|               | Dominant      | 0.122 | 0.294 | 0.821 | 0.979 | 0.998 |
|               | Log-additive  | 0.024 | 0.070 | 0.453 | 0.893 | 0.988 |
| Drinkers      | Codominant    | 0.080 | 0.207 | 0.741 | 0.967 | 0.997 |
|               | Dominant      | 0.39 (1.42–3.83) | 0.002 | 0.007 | 0.077 | 0.437 | 0.886 |
|               | Log-additive  | 0.024 | 0.070 | 0.453 | 0.893 | 0.988 |

SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval
The level of false-positive report probability threshold was set at 0.2, and noteworthy findings are presented
Bold indicate that the level of false-positive report probability threshold < 0.2
variants may have important effect on ONFH pathogenesis. The complexity of the genetic interaction network in ONFH occurrence need to further investigate.

However, some intrinsic limitations should be considered. First, all participants are limited to the Han Chinese population, therefore, whether our finding are applicable to other populations requires further research to confirm. Second, this is a hospital-based, single-center study, so the selection bias cannot be excluded. Third, the mechanism of FTO rs62033406 A>G on the occurrence of ONFH is still unclear, and the analysis of biological functions is needed to further research. Despite the above limitations, our research results provide scientific evidence for the impact of FTO on the risk of ONFH in future studies.

**Conclusion**

To sum up, our results provide new light on the contribution of FTO polymorphisms to ONFH susceptibility among the Chinese Han population, which may offer the new candidate genes for elucidating the pathogenesis of ONFH. However, larger-scale prospective studies and functional
### supplementary information

**Acknowledgements**

The authors thank all participants in the study.

**Author contributions**

YW: drafted the work or revised critically for important content; WZ: performed the experiments; SW and YY: analyzed the data; BZ: conceived and designed the experiments. All authors have read and approved the manuscript.

**Funding**

This work was supported by 2020 the Doctoral Research Fund of Affiliated Hospital of Weifang Medical University (2020BSQD11) and Medical and Health Science and Technology Development Project of shandong province (20210407547).

**Availability of data and materials**

Data supporting the findings of this study are available from the Corresponding Author (Bing Zhu), but their availability is limited, they are used under the data sharing agreement.

**Declarations**

**Ethics approval and consent to participate**

This study protocol was in accordance with the Declaration of Helsinki and its associated risk factors in the Chinese population: results from a nationally representative survey. Chin Med J. 2015;128(1):2043–50.

2. Zhao DW, Yu M, Hu K, Wang W, Yang L, Wang BJ, Gao XH, Guo YM, Xu YQ, Wei YS, et al. Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: results from a nationally representative survey. Chin Med J. 2015;128(2):1423–7.

3. Yu Y, Zhang Y, Wu J, Sun Y, Xiong Z, Niu F, Lei L, Du S, Chen P, Yang Z. Genetic polymorphisms in IL1B predict susceptibility to steroid-induced osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteopors Found USA. 2019;30(4):871–7.

4. Huang R, Zhan Q, Hu W, Yang R, Cheng N, Han Y, Yue X. Association of ABCB1 and CYP450 gene polymorphisms and their dna methylation status with steroid-induced osteonecrosis of the femoral head in the Chinese population. Genet Test Mol Biomarkers. 2020;24(12):789–97.

5. Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev Off J Int Assoc Study Obes. 2008;9(3):246–50.

6. Zhang Q, Riddle RC, Yang Q, Rosen CR, Guttridge DC, Dirckx N, Faugere MC, Faith CR, Clemens TL. The RNA demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2021;43(5):1311–23.
14. Tran B, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between fat-mass-and-obesity-associated (FTO) gene and hip fracture susceptibility. Clin Endocrinol. 2014;81(2):210–7.
15. Guo Y, Liu H, Yang TL, Li SM, Li SK, Tian Q, Liu YJ, Deng HW. The fat mass and obesity associated gene, FTO, is also associated with osteoporosis phenotypes. PloS ONE. 2011;6(1):e23712.
16. Panoutisopoulou K, Metrustry S, Doherty SA, Laslett LL, Maciewicz RA, Hart DJ, Zhang W, Muir KR, Wheeler M, Cooper C, et al. The effect of FTO variation on increased osteoarthritis risk is mediated through body mass index: a Mendelian randomisation study. Ann Rheum Dis. 2014;73(12):2082–6.
17. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434–42.
18. Zhuo Z, Lu H, Zhu J, Hua RX, Li Y, Yang Z, Zhang J, Cheng J, Zhou H, Li S, et al. METTL14 gene polymorphisms confer neuroblastoma susceptibility: an eight-center case-control study. Mol Ther Nucl Acids. 2020;22:17–26.
19. Deng X, Su R, Stanford S, Chen J. Critical enzymatic functions of FTO in obesity and cancer. Front Endocrinol. 2018;9:396.
20. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nuc Acids Res. 2012;40:D930-934.
21. Sinnott-Armstrong N, Sousa IS, Laber S, Rendina-Ruedy E, Nitte Dankel SE, Ferreira T, Meligren G, Karasik D, Rivas M, Pritchard J, et al. A regulatory variant at 3q21.1 confers an increased pleiotropic risk for hyperglycemia and altered bone mineral density. Cell Metab. 2021;33(3):615-628.e613.
22. Mendonça MS, Mangiacavochi PM, Rios AFL. Regulatory functions of FKBP5 intronic regions associated with psychiatric disorders. J Psychiatr Res. 2021;143:1–8.
23. Berulava T, Horsthemke B. The obesity-associated SNPs in intron 1 of the FTO gene affect primary transcript levels. Eur J Hum Genet EJHG. 2010;18(9):1054–6.
24. Vardhan H, Tripathy SK, Sen RK, Aggarwal S, Goyal T. Epidemiological profile of femoral head osteonecrosis in the north Indian population. Indian J Orthop. 2018;52(2):140–6.
25. Tan B, Li W, Zeng P, Guo H, Huang Z, Fu F, Gao H, Wang R, Chen W. Epidemiological study based on china osteonecrosis of the femoral head database. Orthop Surg. 2021;13(1):153–60.
26. Tani T, Ando W. Geographic distribution of the incidence of osteonecrosis of the femoral head in Japan and its relation to smoking prevalence. Modern Rheumatol. 2021;118:1–7.
27. Wen Z, Lin Z, Yan W, Zhang J. Influence of cigarette smoking on osteonecrosis of the femoral head (ONFH): a systematic review and meta-analysis. Hip Int J Clin Exp Res Hip Pathol Ther. 2017;27(5):425–35.
28. Yoon BH, Kim TY, Shin IS, Lee HY, Lee YJ, Koo KH. Alcohol intake and the risk of osteonecrosis of the femoral head in Japanese populations: a dose-response meta-analysis of case-control studies. Clin Rheumatol. 2017;36(11):2517–24.
29. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001;69(1):138–47.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.